2015 - Sanofi

Skip to main content

December 28, 2015

Dengvaxia® First Dengue Vaccine Approved in Brazil

December 23, 2015

Sanofi Submits New Drug Application for the Once-Daily Fixed-Ratio Combination of Insulin Glargine and Lixisenatide

December 22, 2015

Sanofi Pasteur's Dengue Vaccine Approved in the Philippines

December 15, 2015

Sanofi and Boehringer Ingelheim Enter Exclusive Negotiations on Business Swap : Sanofi Would Become a Global Leader in Consumer Healthcare and Boehringer Ingelheim Would Become Second largest Anima...

December 9, 2015

Sanofi: Dengvaxia®, World's First Dengue Vaccine, Approved in Mexico

November 30, 2015

Sanofi: First Doses of Injectable Polio Vaccine ShanIPV(TM) Soon Available for Indian Infants

November 24, 2015

Sanofi and Regeneron Announce 18,000-Patient ODYSSEY OUTCOMES Trial of Praluent® (alirocumab) Injection Fully Enrolled

November 20, 2015

Sanofi and AstraZeneca Exchange More Than 200,000 Chemical Compounds

November 19, 2015

Sanofi Announces Commitment to COP21

November 18, 2015

Xavier Darcos appointed President of the Sanofi Espoir Foundation

November 9, 2015

Sanofi Pasteur Reveals its Research on a "Universal" Influenza Vaccine

November 8, 2015

Sanofi and Regeneron Present Results from Pivotal Phase 3 Study of Sarilumab at American College of Rheumatology Annual Meeting

November 6, 2015

Sanofi and Lexicon Pharmaceuticals to Collaborate on Sotagliflozin, an Investigational New Oral Medicine for People with Diabetes

November 6, 2015

Sanofi Sets Out Strategic Roadmap for Long-term Growth

November 5, 2015

Sanofi and Hanmi Announce License Agreement To Develop Portfolio of Long-Acting Diabetes Treatments

November 4, 2015

Sanofi and the Institut Pasteur reward four researchers for their major contributions in the service of health

November 3, 2015

Sanofi and BioNTech Announce Cancer Immunotherapy Collaboration and License Agreement

October 29, 2015

Sanofi grew sales and business EPS(1) in Q3 2015

October 8, 2015

Treatment Effects Maintained Over Five Years in Majority of Patients with Relapsing Remitting Multiple Sclerosis who Received Genzyme's Lemtrada® (alemtuzumab) in Clinical Trials

October 7, 2015

Sanofi: New Analysis Suggests Aubagio® (teriflunomide) Slows Brain Atrophy in People with Relapsing Multiple Sclerosis

October 1, 2015

Sanofi: Genzyme Opts into Alnylam's ALN-AT3 Hemophilia Program for Development and Commercialization Outside of North America and Western Europe

September 29, 2015

Sanofi New Drug Application for Lixisenatide Accepted for Review by FDA

September 28, 2015

Sanofi Reaches Patent Settlement on Lantus® SoloSTAR®

September 28, 2015

Sanofi and Regeneron Announce Approval of Praluent® (alirocumab) for the Treatment of Hypercholesterolemia in the European Union

September 16, 2015

Sanofi's CSR Achievements Recognized in the Dow Jones Sustainability Indices

September 15, 2015

Sanofi successfully prices EUR 2.0 billion bond issue

September 14, 2015

Sanofi Reports Positive Top-Line Results in Second Pivotal LixiLan Phase III Study

September 1, 2015

Sanofi and Regeneron Announce New Positive Praluent® (alirocumab) Phase 3 Data Presented at ESC Congress 2015

August 31, 2015

Sanofi to Collaborate with Google Life Sciences to Improve Diabetes Health Outcomes

August 10, 2015

Sanofi, Evotec and Apeiron Biologics Enter Collaboration To Develop Novel Small Molecule Immuno-Oncology Treatments

Sanofi, Evotec Enter New Research Collaboration to Discover and Develop Novel Diabetes Therapies

Sanofi : Online Availability of Sanofi Group's Half-Year Financial Report for 2015

Sanofi delivers solid sales and business EPS(1) growth in Q2 2015

Sanofi Announces that First LixiLan Phase III Study Met Primary Endpoint

Sanofi and Regeneron Launch Major New Immuno-Oncology Collaboration

New England Journal of Medicine Publishes New Analyses Confirming that Sanofi Pasteur's Vaccine Candidate Safely Protects Pre-Adolescents to Adults Against Dengue

Sanofi: Genzyme Strengthens Endocrinology Portfolio with Acquisition of Rare Disease Therapy Caprelsa® (vandetanib) from AstraZeneca

Sanofi and Regeneron Announce FDA Approval of Praluent® (alirocumab) Injection, the First PCSK9 Inhibitor in the U.S., for the Treatment of High LDL Cholesterol in Adult Patients

Sanofi and Regeneron Announce CHMP Recommends European Approval of Praluent® (alirocumab) for the Treatment of Hypercholesterolemia

Sanofi Announces New, Global Business Unit Structure to Drive Future Growth

Sanofi: Merial Introduces Oravet® Dental Hygiene Chews for Dogs

Sanofi and Regeneron Announce Phase 3 Results Showing LDL-C Reductions of More Than 60 Percent in Japanese Patients Treated with Praluent® (alirocumab) Injection

Sanofi Extends Collaboration with Medicines for Malaria Venture to Fight One of the World's Deadliest Parasitic Diseases

Sanofi's New Basal Insulin Lantus® XR, Known as Toujeo® in the U.S. and Europe, Approved in Japan for the Treatment of Diabetes Mellitus

Sanofi Signs a Global Agreement with SUEZ environnement To Enhance Water and Waste Management

FDA Advisory Committee Recommends Approval of Sanofi and Regeneron's Praluent® (alirocumab) Injection for Patients with Hypercholesterolemia

Sanofi's Lyxumia® (lixisenatide) Demonstrated Cardiovascular Safety in People with Type 2 Diabetes and High CV Risk

Sanofi Announces Positive Results for Toujeo® in Phase III Study Extension in Japanese People with Uncontrolled Diabetes

Sanofi: FDA Grants Breakthrough Therapy Designation for Genzyme's Olipudase Alfa

Sanofi Hosts German Chancellor Angela Merkel at Frankfurt Site

You are about to leave sanofi.com

If you wish to continue to this external website, click Proceed.

It is provided for information only. Sanofi assumes no responsibility for the information presented on this website.

PROCEED